Montelukast

Montelukast selectively antagonizes the cysteinyl leukotriene receptor CysLT1 on airway smooth muscle and inflammatory cells. By preventing leukotriene binding, it reduces bronchoconstriction, mucus production, vascular leakage, and eosinophilic inflammation, leading to improved breathing and reduced allergic responses.

The appropriate dose of Montelukast is determined by the prescribing healthcare professional based on the patient’s age, weight, and specific indication. Dosage forms may include tablets, chewable tablets, or granules, and the prescriber will provide exact instructions.

Safety data for Montelukast in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their physician, as the drug does pass into breast milk.

To order Montelukast, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who need an add‑on therapy, but it does not replace rescue bronchodilators for acute attacks.

Montelukast should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Montelukast is taken orally, usually once daily in the evening, with or without food. The tablet should be swallowed whole with water; chewable or granule forms are mixed with a small amount of soft food as directed by the prescriber.

Serious risks include neuropsychiatric events such as depression, suicidal thoughts, or mood changes, as well as rare severe skin reactions like Stevens‑Johnson syndrome and angioedema. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with severe hepatic impairment, and it should not be used as a rescue medication for acute bronchospasm.